Valvular & structural heart disease
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry
Authors' conclusion
Redo-TAVI with a balloon-expandable SAPIEN 3 THV platform is a safe and effective reintervention strategy across diverse failed THV types, when guided by the Heart Team, standardised procedural planning, and comprehensive imaging.
Study context
- Population
- Patients with a failed aortic transcatheter heart valve (THV) undergoing redo-TAVI with a balloon-expandable SAPIEN 3 THVenrolled
- Participants
- 143 patients
- Outcome
- Baseline characteristics
Methodological detailsregistry, consecutive patients, 59 international centres, imaging centrally analysed, major clinical events adjudicated by an independent committee
- Registry
- Consecutive patients
- 59 international centres
- Imaging centrally analysed
- Major clinical events adjudicated by an independent committee
Main finding
As reported in the abstract
Median age
84 years
Female
40.6%
Median Society of Thoracic Surgeons risk score
7.0%
Observational data: associations, not effects.
Further findings
Failing THV platform
- Balloon-expandable SAPIEN 3
- 30.1%
- Self-expanding CoreValve/Evolut
- 53.1%
- ACURATE
- 14.0%
Failure mode
- Isolated regurgitation
- 48.6%
- Stenosis
- 35.2%
- Mixed pathology
- 16.2%
Replacement valve successfully implanted
- Successful implantation
- 95.1%
Mortality · 30 days
- 30-day mortality rate
- 3.5%
Mean gradient change
- Overall
- Δ=−12.0 mmHg
- Stenotic failures
- Δ=−29.0 mmHg
Safety
Stroke and pacemaker implantation · 30 days
- Stroke
- 0.7%
- Pacemaker implantation
- 6.3%
Coronary obstruction
- Coronary obstruction
- 1.4%
Original publication
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry. EuroIntervention. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →